313682-08-5

• 常用中文名：Brecanavir
• 常用英文名：Brecanavir
• CAS号：313682-08-5
• 分子式：C₃₃H₄₁N₃O₁₀S₂
• 分子量：703.82300
• 相关类别： 信号通路 代谢酶/蛋白酶 HIV蛋白酶
• 发布时间：2017-10-02 15:34:02
• 更新时间：2024-01-09 15:10:20
• Brecanavir(GW640385)是一种新型、有效的HIV蛋白酶抑制剂。

名称

• 中文名: GW640385
• 英文名: [(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[1,3-benzodioxol-5-ylsulfonyl(2-methylpropyl)amino]-3-hydroxy-1-[4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl]butan-2-yl]carbamate
• 英文别名: Brecanavir; 2fdd; 2fde; GW0385

物化性质

• 密度: 1.43g/cm3
• 分子式: C₃₃H₄₁N₃O₁₀S₂
• 分子量: 703.82300
• 精确质量: 703.22300
• PSA: 191.60000
• LogP: 5.33740
• 折射率: 1.641
• 储存条件: 2-8°C，密封，干燥

生物活性

• 描述: Brecanavir(GW640385)是一种新型、有效的HIV蛋白酶抑制剂。
• 相关类别:
  研究领域 >> 感染
  信号通路 >> 代谢酶/蛋白酶 >> HIV蛋白酶
• 参考文献:

  [1]. Ford SL, Reddy YS, Anderson MT, et al. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 2006;50(6):2201-2206.

  [2]. Reddy YS, Ford SL, Anderson MT, Murray SC, Ng-Cashin J, Johnson MA. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2007;51(4):1202-1208.

合成路线

313679-55-9 ~% 313682-08-5

文献：Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794

313682-03-0 ~% 313682-08-5

文献：Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794

313682-07-4 ~% 313682-08-5

文献：Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794

313681-84-4 ~% 313682-08-5

文献：Miller, John F.; Andrews, C. Webster; Brieger, Michael; Furfine, Eric S.; Hale, Michael R.; Hanlon, Mary H.; Hazen, Richard J.; Kaldor, Istvan; McLean, Ed W.; Reynolds, David; Sammond, Douglas M.; Spaltenstein, Andrew; Tung, Roger; Turner, Elizabeth M.; Xu, Robert X.; Sherrill, Ronald G. Bioorganic and Medicinal Chemistry Letters, 2006 , vol. 16, # 7 p. 1788 - 1794